

#### A. Time-Matched Subcutaneous Tumor: Blood CTCs

# B. Time-Matched Subcutaneous Tumor: Blood CTCs

## 242 Supplemental Figure S1:

243 Time-matched, subcutaneous injection of PC3-GFP-Luc parental population vs.

244 PACC-enriched population: A) Raw cytometric data reporting GFP+ signal across all

blood samples. B) Raw cytometric data reporting DNA content of GFP+ cells across allblood samples.



#### A. Time-Matched Subcutaneous Tumor: Bone DTCs

# B. Time-Matched Subcutaneous Tumor: Bone DTCs

247 Supplemental Figure S2:

Time-matched, subcutaneous injection of PC3-GFP-Luc parental population vs.
 PACC-enriched population: A) Raw cytometric data reporting GFP+ signal across all
 bone marrow samples. B) Raw cytometric data reporting DNA content of GFP+ cells
 across all bone marrow samples.

- 252
- 253

B. Size-Matched Subcutaneous Tumor: Blood CTCs



#### A. Size-Matched Subcutaneous Tumor: Blood CTCs

# 293 Supplemental Figure S3:

Size-matched, subcutaneous injection of PC3-GFP-Luc parental population vs.

295 PACC-enriched population: A) Raw cytometric data reporting GFP+ signal across all

blood samples. B) Raw cytometric data reporting DNA content of GFP+ cells across all

297 blood samples.



#### A. Size-Matched Subcutaneous Tumor: Bone DTCs

#### B. Size-Matched Subcutaneous Tumor: Bone DTCs

298 Supplemental Figure S4:

Size-matched, subcutaneous injection of PC3-GFP-Luc parental population vs.
 PACC-enriched population: A) Raw cytometric data reporting GFP+ signal across all
 bone marrow samples. B) Raw cytometric data reporting DNA content of GFP+ cells

302 across all bone marrow samples.

303



#### B. Caudal Artery Injections: Bone Marrow DTCs



#### 314 Supplemental Figure S5:

- 315 Caudal Artery injection of PC3-GFP-Luc parental population vs. PACC-enriched
- population: A) Raw cytometric data reporting GFP+ signal across all bone marrow
- 317 samples. B) Raw cytometric data reporting DNA content of GFP+ cells across all bone
- 318 marrow samples.

#### A. Caudal Artery Injections: Lung DTCs

B. Caudal Artery Injections: Lung DTCs



## 320 Supplemental Figure S6:

- 321 Caudal Artery injection of PC3-GFP-Luc parental population vs. PACC-enriched
- 322 population: A) Raw cytometric data reporting GFP+ signal across all lung tissue
- 323 samples. B) Raw cytometric data reporting DNA content of GFP+ cells across all lung
- 324 tissue samples.

# 347 Supplemental Figure S7:



- Tail Vein injection of PC3-GFP-Luc parental population vs. PACC-depleted
  parental population: A) Flow-cytometric ploidy analysis of injected cells per injection
  group. B) Proportion of lung DTCs with >4N DNA content across all experimental mice.
  C) Comparative proportions of lung DTCs with >4N DNA content between two injection
  groups.
  - 354

367



# 368 Supplemental Figure S8:

369Tail Vein injection of PC3-GFP-Luc parental population vs. PACC-enriched

population: A) Light microscopy photos and flow-cytometric ploidy analysis of injected

cells per injection group. B) Representative BLI images capturing the cellular distribution

and signal intensity immediately following tail vein injection and 3 days following tail vein

injection. C) Raw cytometric data reporting the presence of >4N Lung DTCs in a pooled

374 sample 21 days following PACC injection.



# 584 Supplemental Figure S9:

PACCs have a pro-metastatic secretory profile: A) Wound-healing assay to measure the differential motility of a PC3-Luc population exposed to parental-conditioned media vs. PACC-conditioned media, where each reported biological replicate is an average of two technical replicates. B) RNA expression of a panel of EMT markers by RTqPCR in a PC3-Luc parental population exposed to parental-conditioned media vs. PACC-conditioned media, were each biological replicate reported is an average of three technical replicates. C) Elisa assay to measure the concentration of IL6 in PACC conditioned media. D) Single cell tracking to measure the effects of addition of Tocilizumab on the motility of a PACCs.